Of the 318 million Americans currently living, 45 million will develop Alzheimer’s disease during their lifetimes if we do not do something to prevent and reverse cognitive decline. Many others will suffer from vascular dementia or Lewy body dementia or other forms of dementia. Loss of mental faculties has become the #1 concern of aging Americans.
Medicine is undergoing a radical transformation, from 20th-century medicine to 21st-century medicine: 20th-century medicine uses small data sets—like looking at sodium and potassium but not the genome or metabolome or epigenome—to attempt to diagnose very complex illnesses in very complicated organisms—human beings. 20th-century medicine makes a diagnosis of what—Alzheimer’s or cardiovascular disease or hypertension—without understanding why.
20th-century medicine uses a one-size-fits-all, monotherapeutic approach, and has been largely unsuccessful in treating chronic illnesses such as Alzheimer’s disease, other neurodegenerative conditions, cancer, and cerebrovascular disease.
21st-century medicine is completely different: larger data sets are used to identify network changes that characterize chronic illnesses, revealing the “why” for each person—this is the etiodiagnosis. Prevention and early symptomatic approaches are emphasized. Addressing the cause of each condition in a comprehensive and personalized, programmatic way leads to improved outcomes, and each program is repeatedly optimized over time, to ensure sustained improvement.
Such an approach was used to bring about the first reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), published in 2014 (Bredesen, Aging 2014).
MPI Cognition was established to provide the research, support, and information to make this approach available to all. We have identified multiple subtypes of Alzheimer’s disease using the extensive metabolic profiling of 21st-century medicine (Bredesen, Aging 2015), identified new and previously unrecognized causes of Alzheimer’s disease (Aging 2016), and developed a continuously evolving version of Dr. Bredesen’s original MEND program.
We hope that this information, research, and support will be valuable to all in our shared goal of reducing the global burden of dementia.